Literature DB >> 1892469

Genetics of diabetes. Trans-racial gene mapping studies.

C H Mijovic, A H Barnett, J A Todd.   

Abstract

A major component of inherited susceptibility to IDDM is associated with one or more loci in the MHC. Identification of the primary susceptibility genes has been complicated by the low frequency of recombination, i.e. linkage disequilibrium, within the MHC. It is difficult to distinguish whether a detected genetic association with the disease is primary, or secondary due to linkage disequilibrium with an allele at another locus which is directly predisposing. During the evolution of different races, however, recombination within the MHC has occurred and population-specific MHC haplotypes exist. Primary susceptibility allels should be associated with disease in all racial groups, regardless of genetic background. It is unlikely that disease associations secondary to linkage disequilibrium will be consistent in these groups. This chapter reviews the known associations of candidate class II susceptibility alleles with IDDM in the five largest racial groups; white Caucasians, Asian Indians, Negroids, Japanese and Chinese. These trans-racial studies suggest that the DQ molecule has a primary role in predisposition to IDDM. There are consistent findings of a positive association with the DQA1*0301 allele and negative associations with the DQB1*0602 and DQB1*0603 alleles. These two alleles differ by a single codon and so the encoded DQ beta chains are likely to have similar functions. DR4-associated susceptibility is associated with the DQA1*0301 allele in all races tested so far but this allele cannot be the only susceptibility factor on this haplotype. The identity of the DR3-associated susceptibility factor remains unclear but the DQB1*0201 allele is a candidate. If DQB1*0201 is involved, the existence of a protective factor on the neutral DR7-DQB1*0201 haplotypes is indicated. Analysis of DR9 associated susceptibility implicates a non-DR/DQ predisposing factor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1892469     DOI: 10.1016/s0950-351x(05)80130-2

Source DB:  PubMed          Journal:  Baillieres Clin Endocrinol Metab        ISSN: 0950-351X


  7 in total

Review 1.  Genetic susceptibility in type 1 diabetes and its associated autoimmune disorders.

Authors:  Akane Ide; George S Eisenbarth
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

2.  Confirmation of an association between rs6822844 at the Il2-Il21 region and multiple autoimmune diseases: evidence of a general susceptibility locus.

Authors:  Amit K Maiti; Xana Kim-Howard; Parvathi Viswanathan; Laura Guillén; Adriana Rojas-Villarraga; Harshal Deshmukh; Haner Direskeneli; Güher Saruhan-Direskeneli; Carlos Cañas; Gabriel J Tobön; Amr H Sawalha; Alejandra C Cherñavsky; Juan-Manuel Anaya; Swapan K Nath
Journal:  Arthritis Rheum       Date:  2010-02

3.  HLA class II DR-DQ amino acids and insulin-dependent diabetes mellitus: application of the haplotype method.

Authors:  A M Valdes; S McWeeney; G Thomson
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

4.  Race-specific type 1 diabetes risk of HLA-DR7 haplotypes.

Authors:  J A Noble; J Johnson; J A Lane; A M Valdes
Journal:  Tissue Antigens       Date:  2011-11

Review 5.  Susceptibility to type 1 (insulin-dependent) diabetes mellitus is determined by MHC class II molecules. What about DR4?

Authors:  C H Mijovic; D Jenkins; M A Penny
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

6.  Analysis of complex human genetic traits: an ordered-notation method and new tests for mode of inheritance.

Authors:  G Thomson
Journal:  Am J Hum Genet       Date:  1995-08       Impact factor: 11.025

7.  Association of particular HLA class II alleles, haplotypes and genotypes with susceptibility to IDDM in the Belgian population.

Authors:  I Buyse; L A Sandkuyl; M Zamani Ghabanbasani; X X Gu; R Bouillon; M Bex; L Dooms; M P Emonds; M Duhamel; P Marynen
Journal:  Diabetologia       Date:  1994-08       Impact factor: 10.122

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.